{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:05:34Z","timestamp":1772197534725,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Start Plan of Shunde Hospital, Southern Medical University","award":["CRSP2022010"],"award-info":[{"award-number":["CRSP2022010"]}]},{"name":"Medical Science and Technology Research Project of Foshan","award":["2320001006951"],"award-info":[{"award-number":["2320001006951"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common chronic diseases. The coexistence of NAFLD and diabetes accelerates the progression of both and tends to induce bad prognosis. To date, lifestyle modification has been suggested as the first-line treatment for NAFLD patients. Some studies indicated that lifestyle modification could normalize glucose levels in newly diagnosed T2DM, but many individuals do not reach glycemic targets in practice using lifestyle modification alone. Considering the tight link between NAFLD and T2DM, metformin, a widely used drug in diabetic patients with a good safety profile, may be a possible treatment or control of NAFLD progression. There is no therapeutic consensus for the treatment of NAFLD patients with diabetes. Therefore, it is essential to elucidate the beneficial effects of lifestyle modification combined with metformin on glucose-lipid metabolism in the NAFLD population with newly diagnosed T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants will be recruited in this single-center, randomized clinical trial through telephone interview. All participants will be assigned randomly at a 1:1:1 ratio to three groups and treated with lifestyle modification including calorie-restricted dietary and exercise therapy, 500\u20132000\u00a0mg\/day metformin, or treated with both lifestyle modification and 500\u20132000\u00a0mg\/day metformin (the co-intervention group) for 12\u00a0weeks. The primary outcomes are changes in glycemic control and severity of fatty liver from baseline to 12\u00a0weeks of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial is designed to clarify whether lifestyle intervention combined with metformin has synergistic effects on glycemic control, attenuating the progression of NAFLD in NAFLD patients with newly diagnosed T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ChiCTR2300072031. Registered on 31 May 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09191-0","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:20:09Z","timestamp":1761906009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-5811","authenticated-orcid":false,"given":"Ke","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuyin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"22","key":"9191_CR1","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263\u201373. https:\/\/doi.org\/10.1001\/jama.2015.5370.","journal-title":"JAMA"},{"issue":"3","key":"9191_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","volume":"47","author":"A Lonardo","year":"2015","unstructured":"Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181\u201390. https:\/\/doi.org\/10.1016\/j.dld.2014.09.020.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"9191_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372\u201382. https:\/\/doi.org\/10.2337\/dc17-1902.","journal-title":"Diabetes Care"},{"issue":"4","key":"9191_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"issue":"2","key":"9191_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2017.173","volume":"14","author":"G Targher","year":"2018","unstructured":"Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99\u2013114. https:\/\/doi.org\/10.1038\/nrendo.2017.173.","journal-title":"Nat Rev Endocrinol"},{"key":"9191_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","volume":"111","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111:154170. https:\/\/doi.org\/10.1016\/j.metabol.2020.154170.","journal-title":"Metabolism"},{"issue":"2","key":"9191_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-78.e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005. quiz e14-5.","journal-title":"Gastroenterology."},{"issue":"8","key":"9191_CR8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.metabol.2015.10.032","volume":"65","author":"SE Mahady","year":"2016","unstructured":"Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1172\u201382. https:\/\/doi.org\/10.1016\/j.metabol.2015.10.032.","journal-title":"Metabolism"},{"issue":"5","key":"9191_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2337\/dc15-1942","volume":"39","author":"S Steven","year":"2016","unstructured":"Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care. 2016;39(5):808\u201315. https:\/\/doi.org\/10.2337\/dc15-1942.","journal-title":"Diabetes Care"},{"issue":"7","key":"9191_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/00365520902845268","volume":"44","author":"JW Haukeland","year":"2009","unstructured":"Haukeland JW, Konopski Z, Eggesb\u00f8 HB, von Volkmann HL, Raschpichler G, Bj\u00f8ro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853\u201360. https:\/\/doi.org\/10.1080\/00365520902845268.","journal-title":"Scand J Gastroenterol"},{"issue":"23","key":"9191_CR11","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1001\/jama.2012.67929","volume":"308","author":"EW Gregg","year":"2012","unstructured":"Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489\u201396. https:\/\/doi.org\/10.1001\/jama.2012.67929.","journal-title":"JAMA"},{"key":"9191_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8491742","volume":"2017","author":"R Zhang","year":"2017","unstructured":"Zhang R, Cheng K, Xu S, Li S, Zhou Y, Zhou S, et al. Metformin and diammonium glycyrrhizinate enteric-coated capsule versus metformin alone versus diammonium glycyrrhizinate enteric-coated capsule alone in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Gastroenterol Res Pract. 2017;2017:8491742. https:\/\/doi.org\/10.1155\/2017\/8491742.","journal-title":"Gastroenterol Res Pract"},{"issue":"9","key":"9191_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1590\/s0004-27302013000900005","volume":"57","author":"H Fan","year":"2013","unstructured":"Fan H, Pan Q, Xu Y, Yang X. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras Endocrinol Metabol. 2013;57(9):702\u20138. https:\/\/doi.org\/10.1590\/s0004-27302013000900005.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"8","key":"9191_CR14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/1753-0407.12555","volume":"9","author":"W Feng","year":"2017","unstructured":"Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800\u20139. https:\/\/doi.org\/10.1111\/1753-0407.12555.","journal-title":"J Diabetes"},{"issue":"3","key":"9191_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.clinthera.2017.01.015","volume":"39","author":"K Yabiku","year":"2017","unstructured":"Yabiku K, Mutoh A, Miyagi K, Takasu N. Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computed tomography and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease. Clin Ther. 2017;39(3):558\u201366. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.015.","journal-title":"Clin Ther"},{"key":"9191_CR16","doi-asserted-by":"publisher","unstructured":"Tian F, Zheng Z, Zhang D, He S, Shen J. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Biosci Rep. (2018) 38(6). https:\/\/doi.org\/10.1042\/bsr20181304.","DOI":"10.1042\/bsr20181304"},{"issue":"2","key":"9191_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20(2):438\u201342. https:\/\/doi.org\/10.1111\/dom.13061.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"9191_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1467-789x.2004.00126.x","volume":"5","author":"D Festi","year":"2004","unstructured":"Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27\u201342. https:\/\/doi.org\/10.1111\/j.1467-789x.2004.00126.x.","journal-title":"Obes Rev"},{"issue":"8","key":"9191_CR19","doi-asserted-by":"publisher","first-page":"E987","DOI":"10.1152\/ajpendo.00133.2013","volume":"305","author":"K Tajima","year":"2013","unstructured":"Tajima K, Nakamura A, Shirakawa J, Togashi Y, Orime K, Sato K, et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl\/6 mice. Am J Physiol Endocrinol Metab. 2013;305(8):E987\u201398. https:\/\/doi.org\/10.1152\/ajpendo.00133.2013.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"9191_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","volume":"69","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2019-318813.","journal-title":"Gut"},{"issue":"2","key":"9191_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97 e10. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043.","journal-title":"Gastroenterology."},{"issue":"11\u201312","key":"9191_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.nut.2009.09.001","volume":"26","author":"MC Elias","year":"2010","unstructured":"Elias MC, Parise ER, de Carvalho L, Szejnfeld D, Netto JP. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition. 2010;26(11\u201312):1094\u20139. https:\/\/doi.org\/10.1016\/j.nut.2009.09.001.","journal-title":"Nutrition"},{"issue":"6","key":"9191_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512.","journal-title":"N Engl J Med"},{"issue":"10","key":"9191_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.nut.2012.01.016","volume":"28","author":"TA Hussain","year":"2012","unstructured":"Hussain TA, Mathew TC, Dashti AA, Asfar S, Al-Zaid N, Dashti HM. Effect of low-calorie versus low-carbohydrate ketogenic diet in type 2 diabetes. Nutrition. 2012;28(10):1016\u201321. https:\/\/doi.org\/10.1016\/j.nut.2012.01.016.","journal-title":"Nutrition"},{"issue":"6","key":"9191_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/nu10060661","volume":"10","author":"LL Wang","year":"2018","unstructured":"Wang LL, Wang Q, Hong Y, Ojo O, Jiang Q, Hou YY, et al. The effect of low-carbohydrate diet on glycemic control in patients with type 2 diabetes mellitus. Nutrients. 2018;10(6):661. https:\/\/doi.org\/10.3390\/nu10060661.","journal-title":"Nutrients"},{"issue":"4","key":"9191_CR26","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/nu6041406","volume":"6","author":"M Georgoulis","year":"2014","unstructured":"Georgoulis M, Kontogianni MD, Yiannakouris N. Mediterranean diet and diabetes: prevention and treatment. Nutrients. 2014;6(4):1406\u201323. https:\/\/doi.org\/10.3390\/nu6041406.","journal-title":"Nutrients"},{"issue":"2","key":"9191_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/jpet.106.110460","volume":"320","author":"Y Minamiyama","year":"2007","unstructured":"Minamiyama Y, Bito Y, Takemura S, Takahashi Y, Kodai S, Mizuguchi S, et al. Calorie restriction improves cardiovascular risk factors via reduction of mitochondrial reactive oxygen species in type II diabetic rats. J Pharmacol Exp Ther. 2007;320(2):535\u201343. https:\/\/doi.org\/10.1124\/jpet.106.110460.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"9191_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2337\/db16-0607","volume":"66","author":"P Ruggenenti","year":"2017","unstructured":"Ruggenenti P, Abbate M, Ruggiero B, Rota S, Trillini M, Aparicio C, et al. Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial. Diabetes. 2017;66(1):75\u201386. https:\/\/doi.org\/10.2337\/db16-0607.","journal-title":"Diabetes"},{"issue":"6","key":"9191_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HJR.0b013e3282efaf50","volume":"14","author":"NP Kadoglou","year":"2007","unstructured":"Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, et al. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil. 2007;14(6):837\u201343. https:\/\/doi.org\/10.1097\/HJR.0b013e3282efaf50.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"10","key":"9191_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2337\/diacare.25.10.1729","volume":"25","author":"DW Dunstan","year":"2002","unstructured":"Dunstan DW, Daly RM, Owen N, Jolley D, De Courten M, Shaw J, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002;25(10):1729\u201336. https:\/\/doi.org\/10.2337\/diacare.25.10.1729.","journal-title":"Diabetes Care"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09191-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:20:11Z","timestamp":1761906011000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09191-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9191"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09191-0","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Shunde Hospital of Southern Medical University. All participants will provide written informed consent before any testing.All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any products that may be evaluated in this article, or claims that may be made by its manufacturer, are not guaranteed or endorsed by the publishers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Informed consent was approved by the ethical committee board in June 2023. Informed consent materials are available from supplementary materials.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"462"}}